Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $1.3 million.

  • Enanta Pharmaceuticals' Depreciation & Amortization (CF) rose 16805.85% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 9631.85%. This contributed to the annual value of $4.6 million for FY2025, which is 9631.85% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Depreciation & Amortization (CF) is $1.3 million, which was up 16805.85% from $1.2 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $1.3 million during Q3 2025, with a 5-year trough of $479000.0 in Q3 2024.
  • In the last 5 years, Enanta Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $716000.0 in 2022 and averaged $775210.5.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Depreciation & Amortization (CF) crashed by 3448.72% in 2022 and then skyrocketed by 16805.85% in 2025.
  • Enanta Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $780000.0 in 2021, then crashed by 34.49% to $511000.0 in 2022, then increased by 25.64% to $642000.0 in 2023, then soared by 38.47% to $889000.0 in 2024, then soared by 44.43% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.2 million for Q2 2025, and $1.2 million during Q1 2025.